CA2318960A1 - Pharmaceutical uses of optically pure (+)-bupropion - Google Patents
Pharmaceutical uses of optically pure (+)-bupropion Download PDFInfo
- Publication number
- CA2318960A1 CA2318960A1 CA002318960A CA2318960A CA2318960A1 CA 2318960 A1 CA2318960 A1 CA 2318960A1 CA 002318960 A CA002318960 A CA 002318960A CA 2318960 A CA2318960 A CA 2318960A CA 2318960 A1 CA2318960 A1 CA 2318960A1
- Authority
- CA
- Canada
- Prior art keywords
- bupropion
- administered
- amount
- pharmaceutically acceptable
- acceptable salt
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Epidemiology (AREA)
- Psychology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Gynecology & Obstetrics (AREA)
- Endocrinology (AREA)
- Reproductive Health (AREA)
- Diabetes (AREA)
- Emergency Medicine (AREA)
- Nutrition Science (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Child & Adolescent Psychology (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7295598P | 1998-01-29 | 1998-01-29 | |
US60/072,955 | 1998-01-29 | ||
PCT/US1999/001952 WO1999038502A1 (en) | 1998-01-29 | 1999-01-28 | Pharmaceutical uses of optically pure (+)-bupropion |
Publications (1)
Publication Number | Publication Date |
---|---|
CA2318960A1 true CA2318960A1 (en) | 1999-08-05 |
Family
ID=22110794
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CA002318960A Abandoned CA2318960A1 (en) | 1998-01-29 | 1999-01-28 | Pharmaceutical uses of optically pure (+)-bupropion |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1051166A1 (ja) |
JP (1) | JP2002501890A (ja) |
AU (1) | AU2483499A (ja) |
CA (1) | CA2318960A1 (ja) |
WO (1) | WO1999038502A1 (ja) |
Families Citing this family (14)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6280763B1 (en) * | 1999-05-10 | 2001-08-28 | Pierce Management, Llc | Apparatus and method for transdermal delivery of bupropion |
US6312716B1 (en) * | 1999-05-10 | 2001-11-06 | Peierce Management Llc | Patch and method for transdermal delivery of bupropion base |
US7671094B2 (en) | 2005-06-27 | 2010-03-02 | Biovail Laboratories International S.R.L. | Bupropion hydrobromide and therapeutic applications |
EP1896002A4 (en) | 2005-06-27 | 2009-11-25 | Biovail Lab Int Srl | BUPROPIONAL SALT FORMULATIONS WITH MODIFIED RELEASE |
US9732031B2 (en) | 2013-12-20 | 2017-08-15 | Deuterx, Llc | Methods of treating neurological and other disorders using enantiopure deuterium-enriched bupropion |
AU2019223187B2 (en) * | 2018-02-23 | 2022-07-28 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US20220249405A1 (en) * | 2018-09-20 | 2022-08-11 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US11291639B2 (en) | 2018-09-20 | 2022-04-05 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US11433035B2 (en) | 2018-09-20 | 2022-09-06 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US20200093760A1 (en) | 2018-09-20 | 2020-03-26 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US11660273B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US11660274B2 (en) | 2018-09-20 | 2023-05-30 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
US11331285B2 (en) | 2018-09-20 | 2022-05-17 | Axsome Therapeutics, Inc. | Dosage forms and methods for enantiomerically enriched or pure bupropion |
EP4031121A4 (en) * | 2019-09-20 | 2022-11-30 | Axsome Therapeutics, Inc. | DOSAGE FORMS AND METHODS FOR FORMING ENANTIOMERICALLY ENRICHED OR PURE BUPROPION |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3885046A (en) * | 1969-12-04 | 1975-05-20 | Burroughs Wellcome Co | Meta chloro or fluoro substituted alpha-T-butylaminopropionphenones in the treatment of depression |
GB9217295D0 (en) * | 1992-08-14 | 1992-09-30 | Wellcome Found | Controlled released tablets |
US5512593A (en) * | 1993-03-02 | 1996-04-30 | John S. Nagle | Composition and method of treating depression using natoxone or naltrexone in combination with a serotonin reuptake inhibitor |
GB9315856D0 (en) * | 1993-07-30 | 1993-09-15 | Wellcome Found | Stabilized pharmaceutical |
WO1996039133A1 (en) * | 1995-06-06 | 1996-12-12 | Neurobiological Technologies, Inc. | Novel n-substituted-2-amino-3',4'-methylene-dioxypropiophenones |
-
1999
- 1999-01-28 WO PCT/US1999/001952 patent/WO1999038502A1/en not_active Application Discontinuation
- 1999-01-28 AU AU24834/99A patent/AU2483499A/en not_active Abandoned
- 1999-01-28 JP JP2000529235A patent/JP2002501890A/ja active Pending
- 1999-01-28 EP EP99904433A patent/EP1051166A1/en not_active Ceased
- 1999-01-28 CA CA002318960A patent/CA2318960A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
EP1051166A1 (en) | 2000-11-15 |
JP2002501890A (ja) | 2002-01-22 |
AU2483499A (en) | 1999-08-16 |
WO1999038502A1 (en) | 1999-08-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US6110973A (en) | Methods for treating obesity and weight gain using optically pure (-)-bupropion | |
TWI298255B (en) | Use of optically pure (s.s)-reboxetine in the manufacture of a medicament for the treatment or prevention of fibromyalgia or another somatoform disorder | |
US20030130355A1 (en) | Therapeutic agents | |
WO1999038503A1 (en) | Pharmacological uses of optically pure (+)-bupropion | |
EP0687472A2 (en) | Potentiation of drug response by a serotonin 1A receptor antagonist | |
JP2003501344A (ja) | (+)−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
JP2003524613A (ja) | (−)−ベンラファキシン誘導体並びにその製造方法および使用方法 | |
CA2138998A1 (en) | Methods and compositions for treating depression and other disorders using optically pure(-) sibutramine | |
JP2001503737A (ja) | 糖尿病の発生を防止するためのシブトラミン類似体の利用 | |
CA2318960A1 (en) | Pharmaceutical uses of optically pure (+)-bupropion | |
CA2139000A1 (en) | Methods and compositions for treating depression and other disorders using optically pure(+) sibutramine | |
EP0759299A1 (en) | Potentiation of serotonin response | |
EP0612242B1 (en) | Use of the pure s(+) isomer of fluoxetine for the preparation of a medicament against migraine headache | |
US20040115263A1 (en) | Use of bupropion for treating restless legs syndrome | |
AU2349899A (en) | Methods and compositions for aiding in smoking cessation and for treating pain and other disorders using optically pure (-)-bupropion | |
AU721924B2 (en) | Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine | |
SK3272001A3 (en) | A new composition | |
WO1992013452A1 (en) | Methods of use and compositions of r(-) fluoxetine | |
AU6172699A (en) | Methods and compositions utilizing pure S()isomer fluoxetine |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FZDE | Discontinued | ||
FZDE | Discontinued |
Effective date: 20050128 |